1
|
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 + T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology 2015; 4:e1017702. [PMID: 26140248 PMCID: PMC4485730 DOI: 10.1080/2162402x.2015.1017702] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/05/2015] [Accepted: 02/06/2015] [Indexed: 12/04/2022] Open
Abstract
Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death and subsequent release of tumor antigens for antigen presenting cells, resulting in the priming of potent tumor-specific immunity. This effect may be further enhanced by immune-stimulating transgenes expressed by the virus. We report a case of a 38-year-old female with Stage 3 metastatic micropapillary serous carcinoma of the ovary. She was treated in a Phase I study with a granulocyte-macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in progressive infiltration of CD8+ lymphocytes into the tumor and concomitant systemic induction of several tumor-specific CD8+ T-cell populations. The patient was alive at the latest follow up more than 20 months after initiation of the study.
Collapse
Affiliation(s)
| | - T Ranki
- Oncos Therapeutics ; Helsinki, Finland
| | - T Joensuu
- Docrates Cancer Center ; Helsinki, Finland
| | - E Jäger
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - J Karbach
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - C Wahle
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - K Partanen
- Docrates Cancer Center ; Helsinki, Finland
| | - K Kairemo
- Docrates Cancer Center ; Helsinki, Finland
| | - T Alanko
- Docrates Cancer Center ; Helsinki, Finland
| | - R Turkki
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - N Linder
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - J Lundin
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - A Ristimäki
- Division of Pathology; HUSLAB and Haartman Institute; Helsinki University Central Hospital ; Helsinki, Finland ; Genome-Scale Biology; Research Programs Unit; University of Helsinki ; Helsinki, Finland
| | - M Kankainen
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - A Hemminki
- University of Helsinki and Helsinki University Central Hospital; Cancer Gene Therapy Group ; Helsinki, Finland
| | - C Backman
- Oncos Therapeutics ; Helsinki, Finland
| | - K Dienel
- Oncos Therapeutics ; Helsinki, Finland
| | | | | | - T Hakonen
- Oncos Therapeutics ; Helsinki, Finland
| | - J Juhila
- Oncos Therapeutics ; Helsinki, Finland
| | | | - P Priha
- Oncos Therapeutics ; Helsinki, Finland
| | | | - S Pesonen
- Oncos Therapeutics ; Helsinki, Finland
| |
Collapse
|